The in Vitro Pharmacological Profile of TD-1211, a Neutral Opioid Receptor Antagonist

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2013 Apr 4

PMID 23549670

Citations 6

Authors

Pamela R Tsuruda

Ross G Vickery

Daniel D Long

Scott R Armstrong

David T Beattie

Affiliations

Soon will be listed here.

Abstract

The clinical efficacy of opioid receptor antagonists for the treatment of opioid-induced constipation (OIC) is established. Peripherally selective antagonists are intended to provide OIC symptom relief without compromising the analgesic effects of centrally penetrant opioid agonists. We describe the in vitro profile of a novel opioid receptor antagonist, TD-1211, at recombinant (human μ and δ, and guinea pig κ) and rodent native opioid receptors. TD-1211 bound with high affinity to human recombinant μ and δ, and guinea pig κ receptors expressed in CHO-K1 cells (pK d = 9.7, 8.6, and 9.9, respectively). The in vitro receptor selectivity of TD-1211 (μ ≈ κ > δ) is similar to that for the peripherally-selective opioid receptor antagonist methylnaltrexone, but contrasts with the μ selectivity of alvimopan. Functionally, TD-1211 behaved as an antagonist at all three receptor types in both recombinant expression systems (pK b = 9.6, 8.8 and 9.5, at μ, δ, and κ, respectively) and rodent native tissue preparations (μ and κ pA2s = 10.1 and 8.8, respectively (guinea pig ileum), and δ pK b = 8.4 (hamster vas deferens)). TD-1211 displayed a high degree of selectivity for opioid receptors over a broad panel of cellular targets. These in vitro data justified investigation of the preclinical in vivo activity of TD-1211 (Armstrong et al., Naunyn-Schmiedeberg's Arch Pharm, 2013).

Citing Articles

Phenol (bio)isosteres in drug design and development.

Dunker C, Schlegel K, Junker A Arch Pharm (Weinheim). 2024; 358(1):e2400700.

PMID: 39580699 PMC: 11726161. DOI: 10.1002/ardp.202400700.

Ligand-Free Signaling of G-Protein-Coupled Receptors: Relevance to μ Opioid Receptors in Analgesia and Addiction.

Sadee W, McKew J Molecules. 2022; 27(18).

PMID: 36144565 PMC: 9503102. DOI: 10.3390/molecules27185826.

Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist.

Long D, Armstrong S, Beattie D, Campbell C, Church T, Colson P ACS Med Chem Lett. 2019; 10(12):1641-1647.

PMID: 31857840 PMC: 6912869. DOI: 10.1021/acsmedchemlett.9b00406.

Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.

Streicher J, Bilsky E J Pharm Pract. 2017; 31(6):658-669.

PMID: 28946783 PMC: 6291905. DOI: 10.1177/0897190017732263.

New Options in Constipation Management.

Davis M, Gamier P Curr Oncol Rep. 2015; 17(12):55.

PMID: 26449843 DOI: 10.1007/s11912-015-0481-x.

References

Walters J, Montagnini M . Current concepts in the management of opioid-induced constipation. J Opioid Manag. 2011; 6(6):435-44. DOI: 10.5055/jom.2010.0042. View

Walsh D . Pharmacological management of cancer pain. Semin Oncol. 2000; 27(1):45-63. View

Smith J, Beattie D, Marquess D, Shaw J, Vickery R, Humphrey P . The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008; 378(1):125-37. DOI: 10.1007/s00210-008-0282-y. View

Yassen A, Olofsen E, Dahan A, Danhof M . Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther. 2005; 313(3):1136-49. DOI: 10.1124/jpet.104.082560. View

Sadee W, Wang D, Bilsky E . Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci. 2005; 76(13):1427-37. DOI: 10.1016/j.lfs.2004.10.024. View

De Luca A, Coupar I . Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996; 69(2):103-15. DOI: 10.1016/0163-7258(95)02053-5. View

Lagrutta A, Trepakova E, Salata J . The hERG channel and risk of drug-acquired cardiac arrhythmia: an overview. Curr Top Med Chem. 2008; 8(13):1102-12. DOI: 10.2174/156802608785700016. View

Sternini C, Patierno S, Selmer I, Kirchgessner A . The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004; 16 Suppl 2:3-16. DOI: 10.1111/j.1743-3150.2004.00553.x. View

Brent P, Chahl L, Cantarell P, Kavanagh C . The kappa-opioid receptor agonist U50,488H induces acute physical dependence in guinea-pigs. Eur J Pharmacol. 1993; 241(2-3):149-56. DOI: 10.1016/0014-2999(93)90196-o. View

10.

Kraft M, MacLaren R, Du W, Owens G . Alvimopan (entereg) for the management of postoperative ileus in patients undergoing bowel resection. P T. 2010; 35(1):44-9. PMC: 2816146. View

11.

Vanegas G, Ripamonti C, Sbanotto A, De Conno F . Side effects of morphine administration in cancer patients. Cancer Nurs. 1998; 21(4):289-97. DOI: 10.1097/00002820-199808000-00011. View

12.

Viscusi E, Gan T, Leslie J, Foss J, Talon M, Du W . Peripherally acting mu-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability. Anesth Analg. 2009; 108(6):1811-22. DOI: 10.1213/ane.0b013e31819e0d3a. View

13.

Seiwald M, Alesch F, Kofler A . [Intraventricular morphine administration as a treatment possibility for patients with intractable pain]. Wien Klin Wochenschr. 1996; 108(1):5-8. View

14.

Kojima Y, Takahashi T, Fujina M, Owyang C . Inhibition of cholinergic transmission by opiates in ileal myenteric plexus is mediated by kappa receptor. Involvement of regulatory inhibitory G protein and calcium N-channels. J Pharmacol Exp Ther. 1994; 268(2):965-70. View

15.

Calderon S, Rothman R, Porreca F, Flippen-Anderson J, McNutt R, Xu H . Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist. J Med Chem. 1994; 37(14):2125-8. DOI: 10.1021/jm00040a002. View

16.

Beattie D, Cheruvu M, Mai N, OKeefe M, Johnson-Rabidoux S, Peterson C . The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn Schmiedebergs Arch Pharmacol. 2007; 375(3):205-20. DOI: 10.1007/s00210-007-0146-x. View

17.

Kurz A, Sessler D . Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003; 63(7):649-71. DOI: 10.2165/00003495-200363070-00003. View

18.

Wade P, Palmer J, McKenney S, Kenigs V, Chevalier K, Moore B . Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist. Br J Pharmacol. 2012; 167(5):1111-25. PMC: 3492991. DOI: 10.1111/j.1476-5381.2012.02068.x. View

19.

Smith J, Amagasu S, Hembrador J, Axt S, Chang R, Church T . Evidence for a multivalent interaction of symmetrical, N-linked, lidocaine dimers with voltage-gated Na+ channels. Mol Pharmacol. 2005; 69(3):921-31. DOI: 10.1124/mol.105.019257. View

20.

Nakayama S, Taniyama K, Matsuyama S, Ohgushi N, Tsunekawa K, Tanaka C . Regulatory role of enteric mu and kappa opioid receptors in the release of acetylcholine and norepinephrine from guinea pig ileum. J Pharmacol Exp Ther. 1990; 254(3):792-8. View